Your session is about to expire
← Back to Search
Motivational Interviewing for Substance Use Disorders
Study Summary
This trial will test whether using Motivational Interviewing at Intake (MII) with adults seeking outpatient addiction treatment leads to better engagement with treatment and understand why this is the case. Personnel feedback will be gathered on whether MII is feasible to implement into standard practice.
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am not experiencing severe mental health issues like psychosis, mania, or suicidal thoughts.I am an adult who speaks English and am seeking treatment for substance use.You need to give your consent electronically.I speak English and work at an outpatient addiction treatment center.You are willing to follow all the study procedures.You have signed a document that says you understand and agree to participate in the study.You have stopped using alcohol or drugs.
- Group 1: Motivational Interviewing at Intake (MII)
- Group 2: Intake as Usual (IAU)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What are the eligibility requirements to participate in this trial?
"Affirmative, the clinical trials database confirms that this medical study is actively recruiting. It was originally published on March 16th 2022 and has since been updated as of August 2nd 2022. Approximately 150 participants will be recruited from a single location."
What is the upper bound for participants in this clinical experiment?
"Correct. Clinicaltrials.gov indicates that this experiment, which was initially opened on March 16th 2022, is actively enrolling participants and requires 150 patients to be recruited from one site."
Who else is applying?
What state do they live in?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Why did patients apply to this trial?
What questions have other patients asked about this trial?
Share this study with friends
Copy Link
Messenger